Antibody Drug Conjugate Market Growth 2019 – Global Players, Segments, Restraints, Demand, Top Trends, Key Developments, Swot Analysis And Regional Forecast To 2023

Antibody Drug Conjugate Market Growth 2019 – Global Players, Segments, Restraints, Demand, Top Trends, Key Developments, Swot Analysis And Regional Forecast To 2023

“Antibody Drug Conjugate Market”
Market Research Future (MRFR) Has Announced a New Release on the Global Antibody Drug Conjugate Market. The primary objective of the report is to analyze the current market landscape and its future potential.

Leading players profiled in the antibody drug conjugate market include Synthon (U.S.), Mersana Therapeutics (U.S.), Oxford BioTherapeutics (U.S.), Heidelberg Pharma (Germany), Progenics Pharmaceuticals (U.S.), Astellas Pharma/Agensys (Japan), Bayer HealthCare (Germany), Agensys, Inc. (U.S.), Concortis Biotherapeutics (U.S.), Genentech (U.S.), AbbVie Inc. (U.S.), Millennium Pharmaceuticals (U.S.), Celldex Therapeutics (U.S.), Pfizer Inc. (U.S.), Immunomedics (U.S.), Antikor (U.K.), Roche Holding AG (Switzerland), ImmunoGen, Inc. (U.S.), and Seattle Genetics (U.S.).

Market Analysis:

The Global Antibody Drug Conjugate (ADC) Market is projected to witness a stupendous growth at a notable 19% CAGR over the predicted years (2017-2023). ADCs are made of three parts- first a specific antibody for binding, an antigen that has limited expression on the normal cells, second a cytotoxic agent to kill target cancer cells and third a chemical linker to attach the cytotoxic agent to the antibody. This is how antibody drug conjugates work. They are the new age of therapeutic agents. One of the key advantages of antibody drug conjugates is that this will help in bringing together the finest characteristics of both antibodies as well as the chemotherapy’s cytotoxic potential.

Request Free Sample Copy at https://www.marketresearchfuture.com/sample_request/1113

There are many factors that is fueling the growth of the antibody drug conjugate market. The different market trends and factors in this market according to an analysis performed by Market Research Future (MRFR) include increasing prevalence of cancer, advancement in medical technology, increased investment in R & D, efficacy of ADC in treating diseases, rising collaboration amid biotechnology and biopharmaceuticals and research institutes, preclinical research, growing geriatric population and rise in obese population. On the contrary, the soaring cost related to the procedure may hamper the growth of the antibody drug conjugate market.

Market Segmentation

As per MRFR report, the global antibody drug conjugate market is segmented on the basis of type, product, technology, application and end-user.

Based on type, it is segmented into drug/toxin, linker, monoclonal antibodies and others. Of these, the antibody drug conjugate linker is expected to have the maximum share in the antibody drug conjugate market.

Based on application, the antibody drug conjugate market is segmented into lymphoma, multiple myeloma, solid tumors, skin cancer, breast cancer, colon cancer, lung cancer, glioblastoma, ovary cancer, pancreas cancer, kidney cancer, prostate cancer and leukemia. Leukemia is further segmented into Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML), and Acute Myeloid Leukemia (AML). Of these, breast cancer had the maximum share owing to its increasing prevalence.

Based on product, it is segmented into Kadcyla, Adcertis and others.

Based on technology, the antibody drug conjugate market is segmented into Immunomedics technology, Seattle Genetics technology, ImmunoGen technology and others.

Based on end-user, it is segmented into biopharmaceutical companies, biotechnology companies, academic research institutes, specialized cancer and others.

Regional Analysis

Based on region, the antibody drug conjugate market covers growth opportunities and latest trends across North America, Europe, Asia Pacific and Middle East and Africa. Of these, North America is expected to accrue maximum share in the market due to advancement in manufacturing techniques, technological innovation and contribution of nanotechnology to create ADC. The U.S. FDA has given approval to only three ADC. The antibody drug conjugate market in Europe will have the second largest share followed by the APAC region. APAC is an emerging market and the factors that are driving the growth of the market include increasing government initiatives. A good number of products are under the pipeline and such developments are performed under license agreements.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

Continued…

LIST OF TABLES

Table 1 Antibody Drug Conjugate Industry Synopsis, 2017–2023

Table 2 Antibody Drug Conjugate Market Estimates & Forecast, 2017–2023, (USD Million)

Table 3 Antibody Drug Conjugate Market, By Region, 2017–2023, (USD Million)

Table 4 Antibody Drug Conjugate Market, By Type, 2017–2023, (USD Million)

Table 5 Antibody Drug Conjugate Market, By Application, 2017–2023, (USD Million)

Table 6 Antibody Drug Conjugate Market, By Product, 2017–2023, (USD Million)

Table 7 Antibody Drug Conjugate Market, By Technology, 2017–2023, (USD Million)

Table 8 Antibody Drug Conjugate Market, By End-User, 2017–2023, (USD Million)

Table 9 North America Antibody Drug Conjugate Market, By Type, 2017–2023, (USD Million)

Table 10 North America Antibody Drug Conjugate Market, By Application, 2017–2023, (USD Million)

Continued…

Browse more Information on This Report at https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113